38562-01-5 Usage
Description
Prostaglandin F2a tris salt, also known as dinoprost tromethamine, is a synthetic analogue of the naturally occurring prostaglandin F2 alpha. It is an autocrine hormone present in many mammalian tissues and is characterized by its white solid appearance. Prostaglandin F2 alpha stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum.
Uses
Used in Pharmaceutical Industry:
Prostaglandin F2a tris salt is used as an oxytocic and abortifacient agent for inducing luteolysis in cows, sows, and mares. It is administered as a single injection via intramuscular (im) or subcutaneous (sc) routes, with the recommended dosage rate being 25 mg for cows, 10 mg for sows, and 5 mg for mares. Due to its extremely short half-life of only a few minutes, it is rapidly absorbed from the injection site and almost completely cleared following one or two passages through the liver and/or lungs.
Used in Research and Development:
Prostaglandin F2a tris salt is used as a biological research tool for studying the roles and interactions of prostaglandins in various physiological processes. Its close relationship with Prostaglandin E2 (PGE2) makes it an important compound for understanding the biosynthesis and functions of primary prostaglandins, as well as the role of Phospholipase A2 (PLA2) in the biosynthesis of PGF2α.
Brand Name:
Prostin F2 Alpha (Pharmacia & Upjohn) is the brand name for Prostaglandin F2a tris salt, which is used in the pharmaceutical industry for its oxytocic and abortifacient properties.
Originator
Prostin F2A,Upjohn,UK,1972
Indications
Dinoprost tromethamine salt (Prostaglandin F2α tromethamine salt) is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist. Dinoprost tromethamine salt is a luteolytic hormone produced locally in the endometrial luminal epithelium and corpus luteum (CL). Dinoprost tromethamine salt plays a key role in the onset and progression of labour.
Manufacturing Process
A solution of tris(hydroxymethyl)aminomethane (1.645 grams) in 3.0 ml of
water at 60°C is added with vigorous stirring to a solution of PGF2α, (5.00
grams) in 700 ml of acetonitrile which has just been ought to its boiling
point. The vessel which contained the aqueous amine solution is rinsed with
three 0.66 ml portions of water, each rinsing being added with vigorous
stirring to the acetonitrile solution. The mixture is then cooled to 25°C by
immersion of the vessel in cool water. At the cloud point, the vessel wall
(glass) below the liquid surface is scratched vigorously with a glass rod. The
mixture is then maintained at 25°C for 24 hours. The resulting crystals are collected by filtration under nitrogen, washed on the
filter with 50 ml of acetonitrile, and then dried by passing nitrogen at 50°C
through the filter cake for one hour. Drying is completed in an oven at 70°C
for 8 hours to give 5.965 grams of the tris(hydroxymethyl)aminomethane salt of PGF2α in free flowing crystalline form; MP 100°-101°C.
Therapeutic Function
Smooth muscle stimulant
Biochem/physiol Actions
Prostaglandin F2α is induced by uterine-produced oxytocin and acts on the corpus luteum to cause luteolysis and inhibit progesterone production.
Safety Profile
Poison by intraperitoneal, subcutaneous, intravenous, and intramuscular routes. Moderately toxic by ingestion. Human reproductive effects by intervagmal route: terminates pregnancy, effects on fertility. Experimental teratogenic and reproductive effects. When heated to
decomposition it emits toxic fumes of NOx. See also other prostaglandin entries.
Check Digit Verification of cas no
The CAS Registry Mumber 38562-01-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,5,6 and 2 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 38562-01:
(7*3)+(6*8)+(5*5)+(4*6)+(3*2)+(2*0)+(1*1)=125
125 % 10 = 5
So 38562-01-5 is a valid CAS Registry Number.
InChI:InChI=1/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4+,13-12+;/t15-,16+,17+,18-,19+;/m0./s1
38562-01-5Relevant articles and documents
Of the trometamol prostaglandin F2 α synthesis method (by machine translation)
-
, (2017/08/30)
The invention discloses a of the trometamol prostaglandin F2 α synthesis method, as the compound (-) - Corey lactone diol as raw materials, through the oxidation reaction to obtain lactone aldehyde, lactone aldehydechain after the weidiWeidi Greecehuo Naer reaction with - the lower side of the splicing an olefin, the olefin double-carbonyl after reduction to obtain the alcohol, with puncture ylide - wittich reaction the upper side of the obtained prostaglandin F2 α, then the prostaglandin F2 α of the trometamol after crystallization by dissolving of the trometamol prostaglandin F2 α. The synthesis method, without noble metal catalyst, there is little side reaction, high yield, low cost, less pollution, is suitable for industrial production. (by machine translation)
Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom
-
, (2008/06/13)
The present invention relates to spiroimidazolidine derivatives of the formula I in which E, V, W, X, R1and R2have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, such as, for example, rheumatoid arthritis, or allergic disorders. The compounds of the formula I are also inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention also relates to processes for the preparation of the compounds of the formula I, pharmaceutical preparations which contain compounds of the formula I, and methods for treating these disorders.
Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
-
, (2008/06/13)
The present invention provides a novel compound represented by the general formula I; wherein R is H or COR3;R1 is H, R2, phenyl, or COR3, wherein R2 is C1-C5 lower alkyl and R3 is R2 or phenyl;Z is CH2 or O;Y is OH or OCOR3;x is 0 or 1; andX is C1-C5 n-alkyl, C3-C7 cycloalkyl, phenyl, furanyl, thienyl or substituted derivatives thereof, wherein the substituents maybe selected from the group consisting of C1-C5 alkyl, halogen, CF3, CN, NO2, NR42, CO2R4 and OR4 wherein R4 is hydrogen or C1-C5 alkyl and dotted lines represent the presence or absence of a double bond and wavy lines represent a cis or trans bond. These novel compounds are especially useful for treating elevated intraocular pressure (ocular hypertension) and glaucoma.
